

# SESSIONS

## PRE-EVENT ACTIVITIES (MARCH 17)

BIO-Europe Spring  
THE SPRINGTIME PARTNERING EVENT  
Save the date  
March 17–19, 2025 | Milan, Italy

### Pre-event registration and badge pick-up (14:00 - 19:00 CET)

14:00 - 14:30

**Time:** 14:00 – 19:00 CET

**Location:** CCIB Barcelona

Plaça de Willy Brandt 11-14

08019 Barcelona

Spain

### BiotechBikers networking ride

14:30 - 16:00

BiotechBikers networking ride (11:00 - 15:00)

- **When:** Sunday, March 17, 11:00am – 15:00pm (approx.)
- **Where:** Meeting point – [Castelldefels Playa train station](#) (trains every 30 minutes from Barcelona Sant station)
- **What:** Join BiotechBikers for a networking ride through the mountains north of Barcelona. Two rides will be offered (~30km and ~60km), with a chance to re-fuel and network along the way.

Bike rentals are available, with pedals and helmets.

Registration is now closed. Contact [claire@biotechbikers.com](mailto:claire@biotechbikers.com) with any questions.

Please note: This ride is not a city tour. You should have experience riding a road racing bicycle and be comfortable riding at least 2 hours over a route with hills. You do not have to be fast but you do need some fitness.

*SPECIAL NOTE: Following BIO-Europe Spring, BiotechBikers will be heading to Girona for the first BiotechBikers Basecamp. Sign up [HERE](#) to register your interest.*

### Newcomer networking and workshop

16:30 - 18:00

Newcomer networking and workshop

**Date:** Sunday, March 17 2024

**Time:** 16:30 – 18:00 CET

**Location:** CCIB Barcelona (Room 111)

Plaça de Willy Brandt 11-14

08019 Barcelona

Spain

#### Do you answer 'Yes' to either of these questions?:

- Is this your first BIO-Europe Spring® and not sure where to start?
- Are you a returning attendee wanting to maximize your BIO-Europe Spring experience?

If so, you are in the right place. Join the BIO-Europe Spring Newcomer's Program to start your networking early, learn how to navigate all the activities on offer to ensure your priorities are met, and ultimately maximize your ROI. Through this initiative you will learn about best practices and get an exclusive sneak preview of the conference venue on Sunday, March 17.

Here is what is included in the program scheduled for March 17, 2024 | 16:30–18:00:

- Network with other first-time attendees and BIO-Europe Spring seasoned veterans
- Get an exclusive sneak preview of the conference venue and program
- Hone your onsite partnering practices
- The program will wrap up in time to travel to the Welcome Reception at the Museu Marítim de Barcelona, which will start at 19:00.

PLEASE SIGN UP [HERE](#)

### Welcome reception

19:00 - 21:00

**Date:** Sunday, March 17 2024

**Time:** 19:00 – 21:00 CET

**Location:** Museu Marítim de Barcelona

#### Participants

**Speaker:** **Miquel Rodríguez Planas** - Economic Development & Promotion Director, City of Barcelona

# SCHEDULE

## PRE-EVENT ACTIVITIES (MARCH 17) -

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

TIME	BIOTECHBIKERS NETWORKING RIDE (11:00 - 15:00)	NEWCOMER NETWORKING AND WORKSHOP
14:00	14:30 - BiotechBikers networking ride 14:00 - Pre-event registration and badge pick-up (14:00 - 19:00 CET)	14:00 - Pre-event registration and badge pick-up (14:00 - 19:00 CET)
16:00		16:30 - Newcomer networking and workshop
19:00	19:00 - Welcome reception	19:00 - Welcome reception

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

---

## Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)

07:45 - 09:00

Location: **CCIB Barcelona**

Light Breakfast: **served until 10:45**

---

## Partnering: one-to-one meetings (9:00 - 18:30 CET)

09:00 - 09:15

One-to-one meetings at BIO-Europe Spring will be scheduled during the hours below:

Meetings on this day will start at **9:00 - 18:30 CET**.

---

## partneringONE essentials workshop

09:30 - 10:00

partneringONE workshop

Location: **Room 133/134**

This interactive workshop is for delegates new to partnering. What can you expect from partnering, and what do others expect from you? Principles around timing, human nature, and partnering etiquette will be applied to the partneringONE process. This session will give you a clear understanding of tactics to generate the best ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have. This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can't attend a session, drop by the partnering help desk with any questions.

---

## Opening remarks

10:00 - 10:30

Business of Biotech

Location: **Room 112**

## Participants

**Panelist: Oriol Alcoba** - Director of Industry, Government of Catalonia

**Panelist: Claire Macht** - Portfolio Director, Europe, EBD Group

**Panelist: Miquel Rodriguez Planas** - Economic Development & Promotion Director, City of Barcelona

**Panelist: David Thomas** - SVP, Industry Research, Biotechnology Innovation Organization (BIO)

---

## Company creation in the current biotech market

10:30 - 11:15

Business of Biotech

Location: **Room 112**

Two years of challenging public markets have strained the strategies of biotechs and their investors bringing new therapies to patients. But what about companies at their earliest stages, spinning off from academic roots and seeking first-time financial backing? This session unveils insights from a recent Citeline study into Series A funding rounds and reveals the science that continues to attract investment, while discussing the challenges ahead for biotechs at this earliest stage of development. The panel features leaders across the continuum of founders, CEOs and venture capitalists to provide a roadmap for biotechs at this critical point in their maturation. From individual start-ups to big picture VC trends, near-term value inflection points versus a long-term strategy, this panel is essential watching for life science entrepreneurs, investors and the innovation community.

---

## Participants

**Moderator: Daniel Chancellor** - Thought Leadership and Consulting Director, Citeline

**Panelist: Lilian Alcaraz** - VP of Early Innovation Partnering, Johnson & Johnson Innovation

**Panelist: Matthieu Coutet** - Partner, Sofinnova Partners

**Panelist: Stephanie Marrus** - Managing Director, University of California San Francisco

---

## Break and breathe

11:30 - 11:45

Break and breathe

Location: **EBD booth**

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

Sustainability Focus Area: Social Responsibility

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

---

## Lunch

12:00 - 14:00

Lunch

---

## partneringONE power up workshop

12:00 - 12:30

partneringONE workshop

Location: **Room 133/134**

Pick up your lunch and join us for this interactive workshop for delegates familiar with partnering who want to up their game. We will cover best practices for collaborating with colleagues, saving time, increasing response rates and acceptance rates, and partneringONE power features to support optimal partnering etiquette. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have.

This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can't attend a session, drop by the partnering help desk with any questions.

---

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Pharma Company Presentation – Servier

13:30 - 13:45

Therapeutic Insights

**Location: Room 111**

A partner with strong commitment:

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier's long-term vision applies to its partnership philosophy.

A partner with a global presence:

With €4.9Bn of revenue in 2022 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

A partner with proven expertise and experience:

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

A partner you can rely on:

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

### Participants

**Presenter: Alix Scholer-Dahirel** - Director Business Development Oncology, Servier

## Meet the dealmakers in oncology: Insilico Medicine and Menarini

13:45 - 14:30

Therapeutic Insights

**Location: Room 111**

This session unravels the global exclusive license agreement between the Menarini Group and Insilico Medicine for the novel KAT6 inhibitor, a potential treatment for breast cancer and other oncology indications. Hear about the factors which drove Menarini's interest, how the deal got started, the influence of artificial intelligence, the challenges faced in securing the deal and much more.

### Participants

**Moderator: Linda Pullan** - Business Development Consultant, founder, Pullan Consulting

**Panelist: Victoria Balannik** - VP and Global Head of External Innovation and In-Licensing, Menarini Stemline

**Panelist: Michelle Chen** - CBO, Insilico Medicine

## For a greener globe: biopharma's journey towards a sustainable future

14:00 - 14:45

Business of Biotech.

**Location: Exhibit Hall Stage**

Did you know that healthcare systems account for more CO2 emissions than the aviation or shipping sectors? Industry leaders admit that they have a responsibility to implement sustainable strategies for the good of the world. They also see these strategies as strategic differentiators that help them build brand equity and position themselves commercially: as governments and payers increasingly view sustainability as a factor in determining reimbursement rates, there are strong incentives for biopharma businesses to embrace sustainable practices.

But what does sustainability really mean for biopharma, and where can the greatest advances in sustainable biopharma be made?

Join the panel of thought leaders across the life science ecosystem to gain insights and expert perspectives into collaborative initiatives, innovative strategies, and industry-wide commitments, in efforts to advance sustainability in the diverse life science industry. It's time to extend the principle of "first, do not harm" to the planet.

### Participants

**Moderator: Jordi Ferrer** - Investment Director, Ship2B Ventures

**Moderator: Mar Guell** - Director - Sustainable Business, Kreab

**Panelist: Florence Dal Degan** - Senior Director, External Innovation, Ipsen

**Panelist: Joe Hopcraft** - Client Partner, Biotech, IQVIA

**Panelist: Jose Maria Fernandez** - Partner, Aliath Bioventures

**Panelist: Stephane Thiroloix** - CEO, AlgoTx

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Drug Discovery and Development: Ziphius

14:00 - 14:15

Company Presentations: Room 131/132

### Location: Room 131/132

Ziphius, founded in 2019, is a Belgian-based pharmaceutical company with a mission to reduce the global impact of infectious and rare genetic diseases. Through its innovative Platform Technology utilizing self-amplifying RNA (saRNA), the company develops safe and effective biopharmaceuticals, including prophylactic vaccines and gene supplementation therapies.

Located in New York, USA and Merelbeke, Belgium Ziphius focuses on combining self-amplifying saRNA technologies with advanced lipid formulations for targeted delivery. Their primary emphasis lies in the preclinical and early clinical phases, addressing prophylactic vaccines and protein-enhancement therapies for rare genetic disorders.

The Ziphius team consist of complementary highly dedicated experts with a strong entrepreneurial, scientific, clinical, managerial and pharmaceutical background

### Participants

**Presenter: Chris Cardon** - CEO, Ziphius

## Oncology: HanchorBio Inc.

14:15 - 14:30

Company Presentations: Room 133/134

### Location: Room 133/134

HanchorBio Inc. was established by Dr. Liu Scott, Chairman, and Founder, in October 2020 in Taipei. HanchorBio is a clinical-stage global pharma, focused on the research and development of novel biologics in Immuno-Oncology. The mission is to transcend immuno-oncology therapies by developing cutting-edge designer biologics with novel modalities.

### Participants

**Presenter: Sean Jou** - President & Chief Scientific Officer, HanchorBio Inc.

## Drug Delivery: Biorchestra, Inc.

14:15 - 14:30

Company Presentations: Room 131/132

### Location: Room 131/132

Biorchestra specializes in innovative RNA therapeutics for neurodegenerative and other disorders. Our IV-formulated RNA medicines platform combines multiple modalities, chemistry innovations, and deep insights into human genetics to deliver scientific breakthroughs that treat rare and prevalent disorders.

Our toolkit includes proprietary targeting ligands with an IV-formulated, non-lipid polymer and broad RNA cargo chemistry validation (ASO, siRNA, mRNA), providing premier capabilities for designing and delivering durable and potent drug candidates that optimally address disease biology through systemic administration.

Our diverse pipeline includes late pre-clinical programs in Alzheimer's, ALS, and Parkinson's disease and earlier preclinical programs in Retina and Obesity.

### Participants

**Presenter: David Oxley** - CBO, Biorchestra, Inc.

## Oncology: Ability Pharmaceuticals, SA

14:30 - 14:45

Company Presentations: Room 133/134

### Location: Room 133/134

AbilityPharma is a clinical phase 2b biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds inducing autophagy-mediated cytotoxicity selectively in cancer cells.

A phase 2b trial (140 patients), double-blind placebo-controlled with ABTL0812, in METASTATIC PANCREATIC CANCER, as first-line therapy in combination with FOLFIRINOX, is currently ongoing in Spain, USA, France, and Israel.

- 100% of patients already recruited
- First blinded efficacy results available
- Interim analysis available in January 2024
- Unblinded results available in 3Q2024
- Out-licensing agreement intended for late 2024

The clinical trial is assessing the safety and efficacy profile of ABTL0812 in combination with FOLFIRINOX in 140 patients with advanced pancreatic cancer as first-line treatment.

To help funding this trial, we were granted USD 1.9 M in an NIH R01 grant managed by the FDA Orphan Disease Program, and a EUR 5.2 M EIC Accelerator grant from the European Commission H2020 (2.4 grant, 2.8 Equity investment).

In 2020 we finished the phase 2a clinical trial in endometrial and squamous lung cancer patients, as first-line therapy in combination with CarboTaxol with very positive results, showing that ABTL0812 combined with chemotherapy is much superior to chemotherapy alone. In the sqNSCLC arm OVERALL SURVIVAL DOUBLED vs historical controls (from 11 to 22 months).

ABTL0812 causes irreversible cytotoxic autophagy selectively in cancer cells through the induction of ER Stress and Akt blockade. Besides its efficacy as single agent, ABTL0812 has synergistic effect with chemotherapy and has synergistic effect with IO therapies (anti-PD1) and acts on the tumor microenvironment turning cold tumors into hot (immunogenic) tumors.

### Participants

**Presenter: Carles Domenech** - Executive Chairman and CEO, Ability Pharmaceuticals, SA

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Drug Discovery and Development: abc biopply ag

14:30 - 14:45

Company Presentations: Room 131/132

### Location: Room 131/132

abc biopply humanized disease models predict patient response to treatment:

Our proprietary technology creates hundreds of miniature versions of patient organs in a laboratory setting, using both healthy and diseased tissues. Our innovative models bridge the gap in predictability between the lab and the clinic.

We free preclinical models from non-human components whenever possible:

Conventional cellular or animal disease models have shown that the predictability of patient response to treatment is severely limited. Great efforts have been made to humanize mouse models to better predict certain aspects of human physiology and immunology. The abc biopply team has made a significant breakthrough in humanizing upstream 3D cell models through the revolutionary and proprietary 3D CoSeedis in chip communication technology™.

Thanks to exceptional physiological growth conditions and unique ways of intercellular communication, our models are free from non-human components to the greatest extent possible and allow us to mimic specific organs and tissues in culture over long periods of time. Thus, we successfully bridge the translational gap with unparalleled physiological responses and unique statistical predictive power.

### Participants

**Presenter: Arne Faisst** - CEO, abc biopply ag

## Oncology: Tenboron Oy

14:45 - 15:00

Company Presentations: Room 133/134

### Location: Room 133/134

Tenboron is a clinical stage biopharmaceutical company developing novel carriers for biologically targeted cancer radiotherapy called Boron Neutron Capture Therapy, BNCT. BNCT involves delivering boron-10 atoms selectively to cancer cells. When low energy neutron radiation is applied, the boron will react inside the cancer cells destroying them but sparing the surrounding healthy cells. Our spearhead product, an antibody-boron conjugate TB0010 is currently in phase 1 clinical development for recurrent head and neck carcinomas.

### Participants

**Presenter: Juha Jouhki** - CEO, Tenboron Oy

## Drug Discovery and Development: SENISCA Ltd

14:45 - 15:00

Company Presentations: Room 131/132

### Location: Room 131/132

SENISCA is an award-winning biotech from the University of Exeter, focused on modulating RNA biology to treat age-related disease. SENISCA targets the process of cellular ageing (senescence) via the development of RNA senotherapeutics which specifically target the causative molecular mechanisms that drive senescence.

Age-related disease is caused by the failure in basic cell health mechanisms, collectively known as the hallmarks of ageing. 15+ years of world-leading research by SENISCA's founders led to the identification of a novel hallmark of ageing, dysregulated RNA splicing, a fundamental contributor to cellular senescence and ageing. We are leveraging this proprietary knowledge to develop senotherapeutics that specifically reverse senescence for the treatment of age-related disease.

### Participants

**Presenter: Sarah Cole** - CEO, SENISCA Ltd

## Rising leaders in healthcare: pioneers of creativity and innovation

15:00 - 15:45

Business of Biotech

### Location: Room 112

2024 marks the fifth instalment of In Vivo's 'Rising Leaders' list, a groundbreaking compilation that spotlights the trailblazers shaping the future of healthcare. The Rising Leaders list is focused on a diverse cohort of entrepreneurs and innovators who represent the next wave of creativity in the industry. This distinguished list features academics, CEOs of small and mid-sized companies, and rising employees in larger biopharma and MedTech businesses, showcasing a rich tapestry of talent across the healthcare landscape. Not confined by age, these individuals have been recognized for bringing something truly innovative and transformative to the healthcare game.

At Bio-Europe Spring, former stars and company creation experts discuss trends in the industry impacting innovation and risk-taking for the next generation of biopharma leaders.

Delve into their remarkable achievements, talent, creativity, and robust leadership qualities that set them apart. This session is a unique opportunity to gain insights into the dynamic profiles of these rising stars and understand how they are shaping the future of healthcare.

The Rising Leaders series extends beyond this session, offering exclusive interviews with innovators and disruptors, coupled with insights from established industry executives on fostering the next generation of talent and building the best teams.

### Participants

**Moderator: Lucie Ellis-Taitt** - Executive Director - In Vivo, Citeline

**Panelist: Angeli Moeller** - Head of DIGI (Data and Integration Generating Insights), Roche

**Panelist: Miquel Vila-Perello** - CEO, Splice Bio

**Panelist: Sandra Von Meier** - Head of Business Development & Licensing, Debiopharm International SA

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Impact of the Inflation Reduction Act across the life science ecosystem

15:00 - 15:25

Business of Biotech.

### Location: Exhibit Stage Hall

This fireside chat will delve into the domestic and international life sciences sector impact of the Inflation Reduction Act. The discussion will include how the legislation is poised to shape and redefine the landscape, both in the US and abroad, changing research priorities and re-shaping biotech investment internationally.

### Participants

**Panelist: Cartier Esham** - CSO, Biotechnology Innovation Organization

**Panelist: John Murphy** - Chief Policy Officer & Healthcare Counsel, Biotechnology Innovation Organization

## Oncology: Theriva Biologics, Inc.

15:00 - 15:15

Company Presentations: Room 133/134

### Location: Room 133/134

Theriva Biologics (TOVX) is a diversified clinical-stage company developing therapeutics to treat cancer and related diseases in areas of high unmet need. The Company's transformed pipeline includes lead drug candidate, VCN-01, a systemically-administered oncolytic adenovirus (OV) engineered to break down the stroma barrier, which protects tumors from cancer therapies and hides them from the patient's immune system. These unique and differentiated mechanisms are intended to improve the anti-tumor effect of the OV with co-administered chemotherapy and immunology products. Importantly, degrading the stroma can also expose tumor antigens, turning "cold" tumors "hot" and enabling a sustained anti-tumor response by the patient's immune system. VCN-01 is an oncolytic adenovirus designed to overcome critical challenges that have traditionally limited OV therapeutics:

- VCN-01 clinical advancement is strongly supported by a 84-patient Phase 1 clinical program that has provided encouraging safety and clinical data in patients with diverse types of cancer, including PDAC. The incidence of PDAC continues to rise and while it has one of the lowest survival rates among all cancer types, efforts to improve upon the standard of care treatment have largely stalled.

- VCN-01 development and potential commercialization are expected to benefit from Orphan Drug Designations granted by the European Medicines Agency for pancreatic cancer and by the FDA for retinoblastoma.

- VCN-01 has been successfully co-administered with chemotherapies, checkpoint inhibitors, and CAR-T cells and is expected to have broad potential utility in treatment regimens for multiple cancer types.

### Participants

**Presenter: Steven Shallcross** - CEO, Theriva Biologics, Inc.

## Drug Delivery: Mana.bio

15:00 - 15:15

Company Presentations: Room 131/132

### Location: Room 131/132

Mana.bio leverages Artificial Intelligence (AI)/ Machine Learning (ML) to design novel non-viral ex-liver cell-specific RNA delivery solutions. Mana Bio is a biotech start-up leveraging data, machine learning, and high throughput screening to design novel LNPs for extrahepatic delivery of nucleic acid therapeutics and vaccines. Mana was founded by a team of serial entrepreneurs and highly regarded experts in the fields of drug delivery, machine learning, and software development.

Mana built predictive AI models and achieved novel IP-protected in vivo results, including lung-specific delivery of mRNA. The company is now open to leveraging this technology platform for collaborations with biotech and pharma companies to optimize formulations for cell-specific delivery of a wide range of payloads, including mRNA and CRISPR gRNA.

### Participants

**Presenter: Yogev Debbi** - Co-Founder & CEO, Mana.bio

## Oncology: Boryung Co, Ltd.

15:15 - 15:30

Company Presentations: Room 133/134

### Location: Room 133/134

Boryung is a pharmaceutical company based in South Korea and currently has a total of 27 affiliates with a diverse business portfolio ranging from research and development of new drugs to manufacturing and sales of drug products, APIs, and consumer products.

Since its foundation in 1957, Boryung has been innovating and taking on challenges to become an indispensable contributor to human health. Boryung's steady growth is evidenced by increases in both sales and operating profit(s) in 2022 - sales increased by 21% (total sales of 760.5 billion KRW) and operating profit(s) increased by 37% (total operating profit(s) of 56.6 billion KRW). As a result of continuous developments, Boryung has become the major leading company in the domestic pharmaceutical market for hypertension, diabetes, and cancer sectors.

In order to leap forward as the No. 1 pharmaceutical company in South Korea and into a global innovative pharmaceutical company, Boryung continuously strives to focus on strengthening research capabilities and developing innovative medicines with our innovative drug research center.

Based on the diverse R&D experiences accumulated over the past 60 years, Boryung is expanding our research and drug development capacity to NCE(New Chemical Entity) and thus, aggressively investing in anticancer drugs as a future growth catalyst.

Specifically, BR101801 is a first-in-class anticancer drug that triple-inhibits PI3K delta/gamma and DNA-PK and is currently being developed by Boryung as a treatment for peripheral T-cell lymphomas (PTCL).

### Participants

**Presenter: Bong Seog Kim** - CTO, Boryung Co.,Ltd.

## Drug Discovery and Development: MindRank

15:15 - 15:30

Company Presentations: Room 131/132

### Location: Room 131/132

MindRank is a clinical-stage, artificial intelligence (AI)-empowered drug discovery and development company. By leveraging its proprietary AI platforms (PharmKG™, Molecule Dance™ and Molecule Pro™), the company aims to significantly accelerate the drug discovery process and deliver small molecule drugs with desirable efficacy and safety profiles.

### Participants

**Presenter: Zhangming Niu** - Founder & CEO, MindRank

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Oncology: ZTI BIOSCIENCES

15:30 - 15:45

Company Presentations: Room 133/134

### Location: Room 133/134

ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology.

#### [Advantages]

1. Low dose (less cost)

In contrast to conventional chelators/linkers, ZTI's carrier contains large amount of radioisotope, by an iron-oxide nano-particle-based core, possible to makes maximization of anti-tumor efficacy with less dose in human.

2. PK (less toxicity)

TERACARRIER™ incorporates inorganic cores and flexible organic shells, resulting in optimal sizes for renal excretion and pharmacokinetics. As a result, our approach optimizes target efficacy while minimizing renal toxicity.

3. Platform

The TERACARRIER™ demonstrates potential not only in isotope conversion but also in accommodating a diverse range of target ligands as a platform technology. Our potential possibilities are the ADRC, integrating the strengths of both radiopharmaceuticals and ADC, poised to address and overcome these individual drawbacks while maximizing synergistic effects. We envision that our cutting-edge ADRC technology, with its unique capabilities, will emerge as a market leader.

#### [Pipeline]

ZTI-101 utilizes 177Lu for orphan disease (ovarian cancer), targeting IND approval this year. ZTI-201 is using 225Ac, which has strong therapeutic activity, overcoming the technically challenging delivery of high-energy alpha daughters through TERACARRIER™ technology. TERACARRIER™'s versatile platform extends to the new targeting agent applied pipeline, designed for solid tumor treatment using from small molecule to antibody.

#### [Patent]

The patented platform and the patented synthesizer equipment empower us to fully harness the potential of radiopharmaceuticals, marking a significant advancement in cancer treatment.

#### [Financial Growth]

We are currently ongoing efforts to secure \$15 million in Series B funding. We are also strategically planning an IPO in 2025.

## Participants

**Presenter: Jaden Hyungseok Chang** - CEO, ZTI BIOSCIENCES

## Drug Discovery and Development: Verge Genomics

15:30 - 15:45

Company Presentations: Room 131/132

### Location: Room 131/132

Verge Genomics is a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery. Verge was born from the convergence of multiple technological forces, including human genomics, machine learning, biological engineering, and translational medicine, that enable us to decipher complex biological and molecular mechanisms. Our CONVERGE® platform harnesses data from human tissue and human-derived model systems, which we believe increases the likelihood of translational success in the clinic, by using patient data to drive discovery and development. Verge built one of the world's largest proprietary multi-omics databases directly from patient tissue, including from over 1,000 patients with neurodegenerative diseases. We use machine learning to map the complex causes of disease and develop those insights into proprietary drug candidates on internal biology and chemistry platforms. Our lead program is a PIKfyve inhibitor for the treatment of ALS and is currently in a Phase 1 clinical trial. It was discovered entirely from our proprietary CONVERGE® platform and brought from research to the clinic in a rapid timeline of only 4 years. Verge is advancing a robust pipeline of programs in Parkinson's Disease, Frontotemporal Dementia, Progressive Supranuclear Palsy, Schizophrenia, and other devastating diseases with no effective treatments to date. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.

## Participants

**Presenter: Jane Rhodes** - CBO, Verge Genomics

## Oncology: Zymeworks

15:45 - 16:00

Company Presentations: Room 133/134

### Location: Room 133/134

Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody drug conjugates (ADC) and multispecific antibody therapeutics (MSAT) across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit [www.zymeworks.com](http://www.zymeworks.com) and follow @ZymeworksInc on X.

## Participants

**Presenter: David Kroeger** - Associate Director, Business Development, Zymeworks

## Drug Discovery and Development: Triastek, Inc.

15:45 - 16:00

Company Presentations: Room 131/132

### Location: Room 131/132

We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medication through digital product development and continuous manufacturing. We design and develop transformative medications for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation issues, accelerating the development of new drug products and improving the quality of pharmaceuticals.

## Participants

**Presenter: Yulian Zhang** - VP of Global Business Development, Triastek, Inc.



# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Navigating the dealmaking landscape in 2024 and beyond

16:00 - 16:45  
Business of Biotech

**Location: Room 112**

This session dives into the ever-evolving landscape of dealmaking and M&A and unravels the forces reshaping the industry's dynamics. Hear real-world case studies and expert insights on strategies for forging strategic alliances, securing partnerships and driving innovation, to address the healthcare challenges of the future. Whether you're a pharmaceutical executive, investor, or innovator, this session navigates the intricacies of dealmaking and provides guidance for success, in 2024 and beyond.

### Participants

**Moderator: Martina Molsbergen** - CEO, C14 Consulting Group, LLC

**Panelist: Roel Bulthuis** - Managing Partner, Syncona

**Panelist: Lubor Gaal** - CFO, Circio AB

**Panelist: Philippe Lopes-Fernandes** - CBO and Executive VP, IPSEN

**Panelist: Bernd Nosse** - Global Head BD&L Technologies and Research Beyond Borders, Boehringer Ingelheim

## Pharma Company Presentation – Almirall

16:00 - 16:15  
Therapeutic Insights

**Location: Room 111**

Almirall is a leading global biopharmaceutical company focused on Medical Dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life".

Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients' needs. We find solutions for them.

Almirall's 1800 employees are devoted to science in Medical Dermatology. In 2023, we totaled €895 MM of sales through a direct presence in 21 countries with 15 affiliates (US and EU included) and a robust network of regional partners distributing our drugs in 70 additional countries.

Almirall is listed on the Spanish Stock Exchange (ticker:ALM).

We seek building value-creating partnership across the R&D continuum (from early research to late clinical) to make a significant difference in patients' lives.

For more information, please visit our web at [www.almirall.com](http://www.almirall.com)

### Participants

**Presenter: Cristina Carreno** - External Innovation Manager, Almirall

## Oncology: Immuneering Corporation

16:00 - 16:15  
Company Presentations: Room 133/134

**Location: Room 133/134**

Immuneering is a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells.

### Participants

**Panelist: E.B. Brakewood** - CBO, Immuneering Corporation

## Drug Discovery and Development: Evariste

16:00 - 16:15  
Company Presentations: Room 131/132

**Location: Room 131/132**

Evariste is building the next generation of precision medicines using mathematical modelling and machine learning to identify novel targets and generate first-in-class, best-in-class small molecule candidates. We have a strong pipeline of assets ranging from early discovery to late-preclinical compounds undergoing proof-of-concept studies - all of which have been rapidly developed using our AI-powered Target ID, Hit ID and Hit-to-Candidate platforms.

### Participants

**Presenter: Anna Hercot** - CEO, Evariste

## Break and breathe

16:00 - 16:15  
Break and breathe

**Location: EBD booth**

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

Sustainability Focus Area: Social Responsibility

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Paving the path for groundbreaking ATMPs

16:15 - 17:00

Therapeutic Insights

**Location: Room 111**

This session will provide a holistic perspective with insights from industry, regulators, hospitals, and investors on navigating the challenges and opportunities in the Advanced Therapies field, ensuring a well-prepared ecosystem for the upcoming wave of innovative therapies.

### Participants

**Moderator: Robert Fabregat** - CEO, Biocat

**Panelist: Toni Andreu** - Scientific Director, EATRIS

**Panelist: Manel Esteller** - Director, Josep Carreras Leukaemia Research Institute

**Panelist: Alessandra Magnani** - Head of the Advanced Therapies and Immunotherapy Platform, Hospital Sant Joan de Deu

**Panelist: Luis Pareras** - Founder and Managing Partner, Invivo Partners

## Oncology: Antion Biosciences

16:15 - 16:30

Company Presentations: Room 133/134

**Location: Room 133/134**

Antion Biosciences is a cell and gene therapy company developing off-the-shelf products for the treatment and cure of diseases with significant unmet medical needs. We leverage our best-in-class gene silencing platform to unlock safe and highly efficient engineering of multimodal therapies.

### Participants

**Presenter: Marco Alessandrini** - CEO, Antion Biosciences

## Antibodies: Hummingbird Bioscience

16:15 - 16:30

Company Presentations: Room 131/132

**Location: Room 131/132**

We are a clinical-stage biotechnology company with a proprietary and differentiated Rational Antibody Discovery (RAD) platform, developing a broad pipeline of novel, precision therapeutics for the treatment of cancer and autoimmune disease.

We are focused on targets with significant biological validation and disease association that have not been drugged, or are inadequately drugged to date, which we refer to as "hard targets".

### Participants

**Presenter: Angele Maki** - CBO, Hummingbird Bioscience

## Oncology: Exact Therapeutics

16:30 - 16:45

Company Presentations: Room 133/134

**Location: Room 133/134**

Exact Therapeutics, clinical-stage biopharmaceutical company developing a proprietary ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®).

ACT® significantly amplifies the clinical utility of a wide range of therapeutic agents across a multitude of applications, including oncology (chemotherapy and immunotherapy), neurological conditions, and gene therapy.

Exact's primary focus is oncology, followed by CNS. The lead compound is PS101 which is in Phase 1b for liver metastases and a Phase 2 trial in pancreatic cancer is planned for 2H 2024.

EXACT Therapeutics was spun out from GE Healthcare in 2012.

### Participants

**Presenter: Per Walday** - CEO, Exact Therapeutics

## Antibodies: SinoMab BioScience Limited

16:30 - 16:45

Company Presentations: Room 131/132

**Location: Room 131/132**

We are the first Hong Kong-based listed biopharmaceutical company (Stock Code: 03681.HK) dedicated to the research, development, manufacturing and commercialisation of innovative therapeutics for the treatment of immunological diseases and neurological diseases. Headquartered in Hong Kong, we strive to become a leading global biopharmaceutical company for the development of novel drugs to fulfil unmet medical needs through our Hong Kong based innovative R&D, and PRC-based manufacturing capabilities. We have been dedicated to R&D since our inception, and have built a pipeline of mAb-based biologics and new chemical entities addressing indications against a plethora of immunological diseases.

Our flagship product Suciraslimab(SM03) is a potential global first-in-class anti-CD22 antibody for the treatment of rheumatoid arthritis (RA). Phase 3 clinical study results demonstrated its compelling therapeutic effect and safety profile. BLA for Suciraslimab in the treatment of RA was accepted by the NMPA for review in Sep 2023. An IND for neurological diseases, MCI or mild dementia, has also been accepted by the NMPA for review in Nov 2023.

Another core pipeline, SM17, is a potential first-in-class and first-in-target antibody for treating autoimmune and allergic inflammatory diseases via the attenuation of IL-25 signaling. Pre-clinical results indicated it is efficacious in treating atopic dermatitis and asthma. Phase 1 study in the US completed demonstrated good safety profile over existing products.

### Participants

**Presenter: Shawn Shui On Leung** - CEO, SinoMab BioScience Limited

# SESSIONS

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

---

## Antibodies: Innovent Biologics

16:45 - 16:50

Company Presentations: Room 131/132

### Location: Room 131/132

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. Headquartered in China, the company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable illnesses. Its pioneering therapies to treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 20 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit [www.innoventbio.com](http://www.innoventbio.com), or follow Innovent on Facebook and LinkedIn.

### Participants

**Presenter: Astrid Maria Dahl** - COO and Head (Europe) of Innovent Biologics, Innovent Biologics

---

## Evening networking reception

19:00 - 22:30

**Location:** Museu Nacional d'Art de Catalunya

**Time:** 19:00 - 22:30

### Shuttle Bus

18:30 – 19:15 CCIB to Museu Nacional d'Art de Catalunya

21:00 – 22:00 Museu Nacional d'Art de Catalunya to CCIB

# SCHEDULE

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17-19, 2025 | Milan, Italy

TIME	PARTNERINGONE WORKSHOP	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC INSIGHTS	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	BREAK AND BREATHE
07:00	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)
09:00	09:30 - partneringONE essentials workshop 09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	09:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)
10:00		10:00 - Opening remarks 10:30 - Company creation in the current biotech market						
11:00								11:30 - Break and breathe
12:00	12:00 - partneringONE power up workshop		12:00 - Lunch					
13:00					13:30 - Pharma Company Presentation – Servier 13:45 - Meet the dealmakers in oncology: Insilico Medicine and Menarini			

# SCHEDULE

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17-19, 2025 | Milan, Italy

TIME	PARTNERING ONE WORKSHOP	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC INSIGHTS	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	BREAK AND BREATHE
14:00				14:00 - For a greener globe: biopharma's journey towards a sustainable future		14:15 - Oncology: HanchorBio Inc. 14:30 - Oncology: Ability Pharmaceuticals, SA 14:45 - Oncology: Tenboron Oy	14:00 - Drug Discovery and Development: Ziphius 14:15 - Drug Delivery: Biorchestra, Inc. 14:30 - Drug Discovery and Development: abc biopply ag 14:45 - Drug Discovery and Development: SENISCA Ltd	
15:00		15:00 - Rising leaders in healthcare: pioneers of creativity and innovation		15:00 - Impact of the Inflation Reduction Act across the life science ecosystem		15:00 - Oncology: Theriva Biologics, Inc. 15:15 - Oncology: Boryung Co, Ltd. 15:30 - Oncology: ZTI BIOSCIENCES 15:45 - Oncology: Zymeworks	15:00 - Drug Delivery: Mana.bio 15:15 - Drug Discovery and Development: MindRank 15:30 - Drug Discovery and Development: Verge Genomics 15:45 - Drug Discovery and Development: Triastek, Inc.	

# SCHEDULE

DAY 1 - 18/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

TIME	PARTNERING ONE WORKSHOP	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC INSIGHTS	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	BREAK AND BREATHE
16:00		16:00 - Navigating the dealmaking landscape in 2024 and beyond			16:00 - Pharma Company Presentation – Almirall  16:15 - Paving the path for groundbreaking ATMPs	16:00 - Oncology: Immuneeering Corporation  16:15 - Oncology: Antion Biosciences  16:30 - Oncology: Exact Therapeutics	16:00 - Drug Discovery and Development: Evariste  16:15 - Antibodies: Hummingbird Bioscience  16:30 - Antibodies: SinoMab BioScience Limited  16:45 - Antibodies: Innovent Biologics	16:00 - Break and breathe
19:00	19:00 - Evening networking reception	19:00 - Evening networking reception	19:00 - Evening networking reception	19:00 - Evening networking reception	19:00 - Evening networking reception	19:00 - Evening networking reception	19:00 - Evening networking reception	19:00 - Evening networking reception

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Rise & Run

06:30 - 07:30

Led by a local trainer, you will enjoy light sightseeing through the streets of Barcelona.

**WHERE:** Hotel Barcelona Princess Av. Diagonal, 1, Sant Martí, 08019 Barcelona

**DURATION:** 60 minutes, 6:30am – 7:30am

You must register in advance - [REGISTER HERE](#)

## Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)

08:00 - 08:30

Location: **CCIB Barcelona**

Light Breakfast: **served until 10:45**

## Partnering: one-to-one meetings (8:00 - 17:00 CET)

08:30 - 09:00

One-to-one meetings at BIO-Europe Spring will be scheduled during the hours below:

Meetings on this day will start at 8:00 - 17:00 CET.

## A breakfast mingle by the YVC Collective

09:00 - 10:00

Business of Biotech

**Location: Room 112**

## Pharma Company Presentation – Sanofi

09:30 - 09:45

Therapeutic Insights

**Location: Room 111**

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world's poorest countries.

### Participants

**Presenter: Peter Dolan** - Director of Business Development, Out-Licensing, Sanofi

## Navigating the biopharma services landscape: current state and future perspectives

09:30 - 10:15

Ecosystem Innovation

**Location: Exhibit Hall Stage**

BioProcess Insider (a [BioProcess International](#) publication) editorial team sits down with a select panel of experts to reflect on how the quarterly movements of the wider pharma industry are affecting the bio services space. We look at how global events, deal making, and regulatory and tech advancements are determining the factors driving or squeezing production, while also finding time to focus on developments within a key area of the industry.

### Participants

**Moderator: Dan Stanton** - Editor at Bioprocess International and Managing Editor at Informa Connect, Informa Connect Life Sciences

## Neuroscience frontier: identifying opportunities of transformative therapies for neurological conditions

09:45 - 10:30

Therapeutic Insights

**Location: Room 111**

Join expert panelists as they navigate the complexities of neuroscience and delve into the innovative advancements and breakthroughs in neurological therapies. Discover opportunities with the potential to revolutionize the way we understand and address neurological challenges and get a glimpse into transformative therapies that lie ahead.

### Participants

**Moderator: Mike Ward** - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

**Panelist: Khateh Ahmadi** - Head of Search and Evaluation Team, MSD

**Panelist: Clement Gautier** - Head of External Innovation Neuroscience & Rare Disease, IPSEN

**Panelist: Tania Nadal** - Clinical Development Director, Ferrer

**Panelist: Anna Rivkin** - VP, Business Development, Immunology, Cardiovascular, and Neuroscience, Bristol Myers Squibb

## Infectious Diseases and Immunization: IAVI

09:45 - 10:00

Company Presentations: Room 131/132

**Location: Room 131/132**

IAVI is a nonprofit scientific research organization that develops vaccines and antibodies. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

Through scientific and clinical research in Africa, India, Europe, and the U.S., IAVI is pioneering the development of biomedical innovations designed for broad global access. We develop vaccines and antibodies in and for the developing world and seek to accelerate their introduction in low-income countries.

IAVI programs and partnerships are grounded in the regions of the world where the disease burden is the greatest, and our approach emphasizes sustainability. Our network of clinical research center partners in Africa and India helps strengthen in-country research capacity and supports the training and education of the next generation of scientists.

### Participants

**Presenter: Nuno Viegas** - Director of Scientific and External Affairs, IAVI

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## In collaboration with YVC Collective - In sync or offbeat: are the expectations of VCs and entrepreneurs aligned?

10:00 - 10:45

Business of Biotech

**Location: Room 112**

This session explores the intricate dynamics between Venture Capitalists (VCs) and entrepreneurs, examining whether their expectations are in sync or if there exists a discord in understanding. From funding strategies to growth milestones, the panel will delve into the nuances of this crucial relationship. Join us for a thought-provoking discussion on the alignment of expectations and the collaborative efforts needed to navigate the evolving landscape of venture capital and life science startups.

### Participants

**Organizer: Ruben Sebastian** - Senior Associate, Criteria Bio Ventures

**Moderator: Francisca Peixoto** - Co-Founder, LifeLink Ventures

**Moderator: Joana Correia** - Analyst, Aliath Bioventures

**Panelist: Jack O'Meara** - CEO, Ochre Bio

**Panelist: Thomas Tan** - Principal, Sound Bioventures

**Panelist: Valerie Vanhooren** - CEO, Ona Therapeutics

**Panelist: Amanda Wagner** - CEO, Immunitas Therapeutics

## Infectious Diseases and Immunization: ingineeon

10:00 - 10:15

Company Presentations: Room 131/132

**Location: Room 131/132**

ingineeon is a spin-off from the Technical University of Munich. Our mission at ingineeon is to bring breakthrough innovations to patients eagerly awaiting novel treatment options. To achieve this, we develop immunomodulatory next-generation biologics. Currently, our pipeline comprises 11 programs in R&D to late-stage preclinical development status in therapeutic areas such as infectious diseases, hepatology, inflammatory diseases and oncology.

### Participants

**Presenter: Julia Behnke** - Chief Executive, ingineeon

## CNS/Neurology: Neurocentrx Pharma Ltd

10:15 - 10:30

Company Presentations: Room 133/134

**Location: Room 133/134**

Pioneering biopharma company Neurocentrx have developed an abuse-deterrent, oral-ketamine therapy for Treatment-Resistant Depression (TRD), which has the potential to provide a convenient, cost-effective means to reduce the high medical morbidity, socio-economic burden, and individual patient suffering associated with TRD

### Participants

**Presenter: Jeffrey Roix** - CEO, Neurocentrx Pharma Ltd

## Diagnostics/ Technology and Digital Tools: 4D Lifetec AG

10:15 - 10:30

Company Presentations: Room 131/132

**Location: Room 131/132**

4D Lifetec aims to revolutionize early cancer detection. Our proprietary immuno-oncological biomarker DDS, embedded in an easy-to-use blood test, can detect cancer at its earliest stages (I and II), offering peace of mind and proactive well-being protection. Sophisticated artificial intelligence (AI) enhances our immunological high-throughput blood assays which in turn enables timely intervention and treatment.

The Company:

At 4D Lifetec AG, we are healthcare innovators with a clear purpose - to tackle medicine's vital challenges head-on. Comprising a team of distinguished experts, we are on a mission of utmost urgency: detecting cancer early when treatment options are most effective and hope for a cure is strongest.

### Participants

**Presenter: Arne Faisst** - Chairman and Co-Founder, 4D Lifetec AG

## EIB venture debt and its catalytic role in the venture financing ecosystem

10:30 - 11:00

Ecosystem Innovation

**Location: Exhibit Hall Stage**

Venture debt is a very useful funding instrument for innovative, VC backed companies, but its role in Europe is still somewhat limited.

The session aims to raise awareness about this form of funding and demonstrate how the European Investment Bank, the leading venture debt player in Europe, supports innovative life science companies and how borrowers benefit from this form of funding.

### Participants

**Moderator: Christian Soschner** - CEO, CS Life Science Invest

**Panelist: Gergely Krajcsi** - Senior Investment Officer, European Investment Bank

## CNS/Neurology: NEWRON PHARMACEUTICALS SPA

10:30 - 10:45

Company Presentations: Room 133/134

**Location: Room 133/134**

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia.

### Participants

**Presenter: Laura Faravelli** - VP Business Development, NEWRON PHARMACEUTICALS SPA



# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Diagnostics/Technology and Digital Tools: Seek Labs

10:30 - 10:45

Company Presentations: Room 131/132

### Location: Room 131/132

Seek Labs is developing next generation molecular diagnostics technologies that have the potential to revolutionize the detection and treatment of diseases. Point of care diagnostics is currently limited by expensive technologies, the need for specialized equipment, training and temperature controls. Seek has eliminated these barriers, vastly expanding the definition of point of care and opening an array of new global markets for diagnostics and treatments of disease on a global scale. A single device the size of a credit card can now process a sample and generate a test result in under 20 minutes, anytime, anyplace and anywhere.

### Participants

**Presenter: Jared Bauer** - CEO, Seek Labs

## CNS/Neurology: Tonix Pharmaceuticals Holding Corp.

10:45 - 11:00

Company Presentations: Room 133/134

### Location: Room 133/134

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix's development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix's CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead development CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA and submit an NDA for the approval of TNX-102 SL for the management of fibromyalgia in the second half of 2024. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and topline results were reported in the third quarter of 2023. TNX-1900 (intranasal potentiated oxytocin) is being studied in binge eating disorder, pediatric obesity, bone health in autism and social anxiety disorder by academic collaborators under investigator-initiated INDs. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix's rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA.

### Participants

**Presenter: Seth Lederman** - CEO, Tonix Pharmaceuticals Holding Corp.

## Diagnostics/Technology and Digital Tools: GenEndeavor LLC

10:45 - 11:00

Company Presentations: Room 131/132

### Location: Room 131/132

Our goal has been to make an impact on the healthcare and agriculture industries; to break through the technical barriers that exist today.

GenEndeavor has developed novel technology platforms to enable the early detection of genetic and infectious diseases, as well as implement cost-effective trait screening.

It is our vision to bring better therapeutic outcomes to patients, and it is our company's mission to save more lives and feed more people by empowering a new generation of detection technologies.

### Participants

**Presenter: Ricardo Mancebo** - CEO, GenEndeavor LLC

## New generation of life science venture investing

11:00 - 11:45

Business of Biotech

### Location: Room 112

This session explores the transformation of the biotech investment landscape over the last decades, including the diversification of investment scope across various funds. The panelists also unravel what LPs are looking for, beyond financial returns, if pharma's view on external innovation has shifted and highlight the importance of a collaborative mindset.

### Participants

**Moderator: Karen Chan** - Associate, BioGeneration Ventures

**Panelist: Clara Campas** - Managing Partner and Co-Founder, Asabys

**Panelist: Alain Huriez** - Chairman and Managing Partner, Adbio Partners

**Panelist: Laura Lane** - VP - Venture Sciences (Europe), Eli Lilly & Co

**Panelist: Jose Mesa** - Partner, Columbus Venture Partners

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## CNS/Neurology: Addex Therapeutics Ltd

11:00 - 11:15

Company Presentations: Room 133/134

### Location: Room 133/134

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional, non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM) is in a Phase 2 clinical trial for the treatment of epilepsy. The company's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in post-stroke recovery. Indivior PLC has licensed Addex's GABAB PAM program for the development of drug candidates, with a focus on substance use disorder. Addex is also advancing a broad preclinical pipeline, which includes development of a range of GABAB PAM for chronic cough, mGlu7 NAM for stress related disorders, M4 PAM for schizophrenia and other forms of psychosis and mGlu2 NAM for mild neurocognitive disorders and depression. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

### Participants

**Presenter: Tim Dyer** - CEO, Addex Therapeutics Ltd

## Autoimmune/Inflammation: Halia Therapeutics

11:00 - 11:15

Company Presentations: Room 131/132

### Location: Room 131/132

At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses. Founded in 2017, our incredible team of scientists has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.

### Participants

**Presenter: David Bearss** - CEO, Halia Therapeutics

## CNS/Neurology: STALICLA SA

11:15 - 11:30

Company Presentations: Room 133/134

### Location: Room 133/134

Stalicia is a precision neuro clinical stage company. Funded in 2017, Stalicia has raised over \$80m in private capital and non dilutive funding. Stalicia's shareholders include Novartis, Pitced, Edmond de Rothschild and SPRIM.

Stalicia has successfully developed a unique neuro platform, DEPI, with a first application in precision Autism Spectrum Disorder through the clinical development of 2 precision autism assets: STP1 and STP2 entering Phase 2.

Stalicia has also developed a mGluR5 NAM platform with its lead asset, STP7 (mavoglurant) licensed from Novartis, entering Phase III in partnership with the National Institute of Health. Stalicia mGluR5 platform offers multi-faceted late-stage clinical development opportunities in the field of CNS.

STALICLA is now preparing a 65m-Series C to support STP1 & STP2 phase 2, develop STP7 around substance use disorders and additional CNS indications and expand its neuro precision pipeline through the in licensing and development of a new PhII asset for which Stalicia has already secured a \$24m of credit line.

### Participants

**Presenter: Lynn Durham** - CEO & Founder, STALICLA SA

## Autoimmune/Inflammation: Artax Biopharma

11:15 - 11:30

Company Presentations: Room 131/132

### Location: Room 131/132

Artax Biopharma is a clinical-stage biotechnology company transforming the treatment of T Cell-driven autoimmune diseases. Our first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options. Our lead program AX-158 will deliver Phase 2a Proof of Concept study in psoriasis later in 2024. In contrast to agents targeting individual cytokines, we believe our approach will allow us to address a broad spectrum of patients. By having the potential to impact multiple cytokines, we hope to address areas of high unmet need beyond where targeted therapies have achieved success.

We believe there is significant potential for our approach to revolutionize treatment of T Cell-driven diseases. Immunomodulation maintains healthy control of the immune system and addresses the underlying source of T Cell-driven diseases. Central to a well-functioning immune system is the T Cell Receptor (TCR). When TCR signaling becomes dysregulated, it causes T Cell-driven conditions, including autoimmune diseases, and induced T Cell pathologies where medical treatments result in immune reactions (such as stem cell transplants resulting in acute graft-versus-host-disease or immuno-oncology treatments resulting in immune related-adverse events). We believe the immunomodulation mechanism offered by our investigational agents holds broad potential to revolutionize how these T Cell-driven autoimmune diseases are addressed, while not impairing the ability of a patient's immune system to function properly.

Artax Biopharma is based in the Boston area and raised Series A & B from Advent Life Sciences, Sound Bioventures, and Columbus Venture Partners. For more info, see [artaxbiopharma.com](http://artaxbiopharma.com)

### Participants

**Presenter: Chris VanDeusen** - CSO, Artax Biopharma

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## A new home: why is Paris region the ideal base to develop your biotech startups?

11:30 - 12:00

Ecosystem Innovation

### Location: Exhibit Hall Stage

During this session, we will dive into the Paris Region Life Sciences ecosystem and explore how startups can benefit from all its assets. From lab bench to industrialization, we will unveil the thriving journey of a startup inside the #1 European Life Sciences ecosystem with a use case in oncology and bioproduction.

### Participants

**Moderator: Jeremy Herve** - Head of Innovation and Economic Development, EPA Paris Saclay

**Panelist: Frederic Caroff** - CEO, Hephaistos Pharma

**Panelist: Benjamin Garel** - CEO, Paris Saclay Cancer Cluster

**Panelist: Chloe Lepretre** - Head of External Innovation, Servier

## Immuno-Oncology: T-knife Therapeutics

11:30 - 11:45

Company Presentations: Room 133/134

### Location: Room: 133/134

T-knife is creating next-generation T cell therapies for patients with solid tumor cancers. The company's unique approach leverages its MyT platform, a T cell receptor and target identification platform, along with proprietary next-generation enhancements to drive deeper, more durable responses for patients. T-knife is developing a pipeline of TCR-T product candidates; the company's first generation program targeting MAGE-A1 demonstrated safety and POC of the platform in a Phase 1a study. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbrück Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin. The company has raised nearly \$200M to date from leading life sciences investors, and is based in the US and in Germany.

### Participants

**Presenter: Elisa Kieback** - CTO and Founder, T-knife Therapeutics

## Autoimmune/Inflammation: Noa Therapeutics

11:30 - 11:45

Company Presentations: Room 131/132

### Location: Room 131/132

At Noa Therapeutics, we are passionately committed to transforming the treatments of complex immune diseases. We are driven by an intimate understanding of the disappointments and complications that patients face, again and again with current treatment options. We aim to defy this convention, seeing complexity as an opportunity for innovation. We are committed to the development of therapeutics that patients want and need. We envision a future where patients break free of the cycle of treatment failures, where therapeutics provide a return to a high quality of life. We aim to deliver medications for all patients, irrespective of their stage of life or severity of their condition. We aim to delivery disease modification, putting an end to the chronic cycle of current treatment failures. We strive to authentically represents the diverse populations we serve. Our dedication to patients involves offering therapeutics that address previously excluded, underserved, and underrepresented patient populations. Our dedication to our community involves providing growth opportunities and a guiding framework for meaningful innovation. Our dedication drives meaningful change, creating a better future for all.

At Noa Therapeutics, we are committed to being a therapeutic company that listens to the real needs of patients. Our mission is not just about business; it's about making a profound impact on the lives we touch, now and for generations to come.

### Participants

**Presenter: Carla Spina** - CEO, Noa Therapeutics

## Immuno-Oncology: Mestag Therapeutics

11:45 - 12:00

Company Presentations: Room 133/134

### Location: Room 133/134

Mestag harnesses new insights into fibroblast-immune interactions to develop impactful treatments for patients. We are progressing a pipeline of sophisticated first-in-class antibodies designed to improve the lives of patients with cancer and inflammatory disease. Together with our collaboration partner Janssen Biotech, Inc. we are also identifying novel targets for future therapies.

Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women's Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. We are supported by leading life science investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures.

Mestag is headquartered in Cambridge, UK, and in 2021 was recognized on the Fierce 15 list of innovative biotechnology companies.

### Participants

**Presenter: Robert de Jonge** - SVP, Head of Corporate Development, Mestag Therapeutics

## Dermatology: Alphyn Biologics

11:45 - 12:00

Company Presentations: Room 131/132

### Location: Room 131/132

Alphyn is using its AB-101 drug platform to develop safer, more effective therapeutics, initially for the \$118 Billion Atopic Dermatitis (AD) market. After only 3½ years, Alphyn's first drug candidate, topical AB-101a, completed two Phase 2a clinical trials in AD with market-leading results, providing a faster path to regulatory approval and a huge commercial opportunity, with clinical results pointing to it being the "drug of choice" for this vast 800 million patient population.

### Participants

**Presenter: Neal Koller** - CEO, Alphyn Biologics

### Lunch

12:00 - 14:00

Lunch

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Closing the gap: the imperative for women's health in biopharma

12:00 - 12:45  
Therapeutic Insights

**Location: Room 111**

Women, on average, spend 25% more time in poor health than men. "Closing the Women's Health Gap: A \$1 Trillion Opportunity to Improve Lives and Economies," a report published by the McKinsey Health Institute in collaboration with the World Economic Forum Center for Health and Healthcare, redefines Women's Health and explores the root causes driving this discrepancy and outlines the actions needed to address the shortcomings that limit the ability of many women to live to their full potential. Closing the gender health gap could reduce the time women spend in poor health by almost two-thirds and add up to \$1 trillion to the economy annually by 2040, the report says. It could also lead to an additional seven healthy days for every woman each year, or more than 500 days over a woman's lifetime. For every \$1 invested in women's health, ~\$3 is projected in economic growth, generating the equivalent impact of 137 million women accessing full-time positions by 2040, the research finds.

The session will entail a 10-minute presentation of the "Closing the Women's Health Gap" report findings, followed by a panel discussion with different stakeholders of the HC ecosystem. Attendees will hear about the most pressing challenges in addressing the women's health gap, explore the most promising opportunities that biopharma executives can action against, and learn from panelists' experiences in embedding women's health into their organizations and operations.

### Participants

**Moderator: Anouk Petersen** - Partner, McKinsey & Company

**Panelist: Cartier Esham** - CSO, Biotechnology Innovation Organization

**Panelist: Hakan Goker** - Managing Director, M Ventures

**Panelist: Guillem Laporta** - Partner, Ysios Capital

## Oncology: NUAgO Therapeutics Inc

12:00 - 12:15  
Company Presentations: Room 133/134

**Location: Room 133/134**

In 2023, the U.S. confronted nearly 2 million new cancer cases and over 600,000 deaths. We need better treatments. Advancements in precision medicine, including targeted therapy and immunotherapy, show promise, but the challenges of genetic variation, tumor heterogeneity, and treatment resistance limit therapeutic benefit to a fraction of cancer patients. The lack of reliable predictive immunotherapy markers limits delivering long-term survival benefits to most patients. We urgently need innovative, effective solutions that overcome the challenges of precision medicine.

NUAgO Therapeutics, Inc. is pioneering a transformative approach that directly addresses these challenges. Born from over ten years of dedicated research at Northwestern University, our technology charts an entirely new course for the future of precision medicine by tackling the challenges of genetic variation.

NUAgO Therapeutics offers a unique opportunity, combining a scientifically solid foundation with a leadership team having a clear strategic vision for addressing critical gaps in cancer treatment. Our technology is not just a new therapy; it's a new way of treating cancer, promising a significant impact on patient outcomes. We seek strategic partners and early-stage investors to support our pre-clinical studies targeting late 2025 / early 2026 IND submission. We invite investors to join us on this journey to transform cancer care and deliver substantial value to stakeholders and society.

### Participants

**Presenter: Robert Schickel** - CEO, NUAgO Therapeutics Inc

## Ophthalmology: Guangzhou Ocusun Ophthalmic Biotechnology Co.Ltd

12:00 - 12:15  
Company Presentations: Room 131/132

**Location: Room 131/132**

Ocusun is a high-tech innovative ophthalmic company located in Guangzhou, China, specializing in the research and development, production, and sale of innovative drugs. The company boasts proprietary treatments for conditions such as cataracts and glaucoma, and is powered by an elite team of scientists, ophthalmic clinical groups, and an international research and development base. Ocusun is founded and chaired by Dr. Li Hanxiong.

Renowned for its groundbreaking drug developments in the field of ophthalmic medicine, Ocusun captures the spotlight with its extensive and modern international research and development base situated in Guangzhou. Covering an area of 6,000 square meters, the facility profoundly illustrates Ocusun's commitment to scientific research and technological advancement. This expansive research complex is not only equipped with advanced laboratory facilities and research instruments, but it also fosters an ideal setting for interdisciplinary collaboration and the exchange of innovative ideas.

Operating on this international level, Ocusun's research and development team-comprising distinguished scientists and ophthalmic experts-is dedicated to creating advanced treatments for ophthalmic diseases such as cataracts and glaucoma. Working within this spacious and potential-laden base, Ocusun's professionals are at the forefront of ophthalmic drug research, ensuring that the company's products meet the rigorous standards of the global market.

Guided by Dr. Li Hanxiong and Dr. Tang Peng Cho, Ocusun is advancing towards global leadership in ophthalmology with innovative products that meet clinical needs. Dr. Li's strategic vision and Dr. Tang's extensive experience drive the company's R&D direction. Together, they nurture a culture of innovation at Ocusun, aiming to improve vision health worldwide.

### Participants

**Presenter: Peng Cho Tang** - CSO, Guangzhou Ocusun Ophthalmic Biotechnology Co.Ltd

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Break and breathe

12:30 - 12:45

Break and breathe

**Location:** EBD booth

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

Sustainability Focus Area: Social Responsibility

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

## Pharma Company Presentation – MSD

12:45 - 13:00

Company Presentations: Room 133/134

**Location:** Room 133/134

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD's development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. We operate in more than 140 countries and had sales of more than \$48 billion in 2022.

### Participants

**Presenter:** **Richard Reschen** - Director, BD&L European Search and Evaluation, MSD

## Perspectives for partnering success: communicating commercial appeal of early-stage assets

13:00 - 13:45

Business of Biotech

**Location:** Room 112

What green and red flags do pharmaceutical companies look for from a commercial perspective when evaluating an early-stage biotech company for a potential deal or investment? This is a must for early-stage biotech leaders – learn what can be done as you head toward key milestones to make a deal an easy decision for a commercially-minded partner.

### Participants

**Moderator:** **Mike Ward** - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

**Panelist:** **Nick Dunscombe** - VP, Head of New Product Planning, Astellas Pharma Inc., Astellas Global

**Panelist:** **Tim Dyer** - CEO, Addex Therapeutics Ltd

## Day in the life of an experienced dealmaker

13:00 - 13:45

Business of Biotech.

**Location:** Room 111

This ever-popular session takes a deep dive into the current state of the life sciences industry with the expertise of today's leading pharma dealmakers and venture investors. Join this engaging discussion to learn how to navigate the current climate of the biotech industry.

### Participants

**Moderator:** **Anton Gueth** - Managing Director, EVOLUTION Life Science Partners

**Moderator:** **Evonne Sepsis** - Founder and Managing Director, ESC Advisors

**Panelist:** **Matthias Mullenbeck** - SVP, Head Global Business Development & Alliance Management, Merck KGaA

**Panelist:** **Michael Palladinetti** - Global Head of Business Development & Licensing, Sanofi

**Panelist:** **Nigel Sheail** - Venture Partner, Versant Ventures

## Metabolic Diseases: Caledon Bioscience Inc.

13:00 - 13:15

Company Presentations: Room 133/134

**Location:** Room 133/134

Caledon Biosciences is a new startup which has acquired the key assets from the shell of Liminal Biosciences, a former NASDAQ listed company which was taken private by the principal investor, Thomvest Asset Management Inc. which is the investment arm of Canada's wealthiest family and owners of Thomson Reuters. Now that the take-private has been finalized and go forward operations have been streamlined, Caledon Bioscience Inc. has been spun off, is Seed funded by Thomvest and are now in the process of seeking private, VC co-investors to help take the company through to the next value inflection points. Thomvest are not your typical biotech investors and although they have signified their willingness to participate in future financings, we are looking to expand the investor base with experienced biotech investors.

Given the recent streamlining of business operations, Caledon is as capital efficient as possible and we are able to leverage the resources of our lead program to move the others programs forward at modest cost. We are based in Montreal, Canada with operations in Cambridge, UK.

We have a pipeline of 3, small-molecule assets focused on GPCR targets implicated in inflammation, fibrosis and metabolic disease, the first of which, a selective GPR84 antagonist for NASH/NAFLD will be in the clinic in before the end of this year. Our CTA has recently been submitted. Our second asset, another selective antagonist, targets OXER1 for the treatment of eosinophilic driven disease. On this program we have selected the lead candidate and are getting ready to commence CTA enabling activity. We intend to tackle eosinophilic asthma and atopic dermatitis with this compound. Finally, we have a selective GPR40 agonist for the treatment of metabolic disease and T2D.

### Participants

**Presenter:** **Bruce Pritchard** - CEO, Caledon Bioscience Inc.

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Metabolic Diseases: Ciloa

13:15 - 13:30

Company Presentations: Room 133/134

### Location: Room 133/134

Ciloa is a French preclinical biotechnology company, spin-off from the CNRS and the University of Montpellier, with the world's leading experience in the development of exosome-based vaccines and therapeutic vectors. Ciloa has a unique patented technology for bioengineering exosomes with any functional protein at the membrane or in the cytosol. This technology is supported by a state-of-the-art in-house cleanroom manufacturing facility to produce GMP-like exosomes.

The company operates as a highly versatile platform (ongoing collaborations with big pharma, big biotech and academia) that can tackle a wide range of inherited and acquired pathologies. Ciloa has developed a pipeline of biotherapeutic candidates for diabetes, metabolic, inflammatory and cardiovascular diseases, and oncology, as well as several vaccine candidates for emerging viral diseases. They are at various stages of development, from research to regulatory pre-clinical phases.

Our lead candidate, the Adiponectin-Exosome, offers a new therapeutic approach to metabolic diseases by interfering with the origin of these pathologies, namely inflammation and oxidative stress. This approach has already proved its worth in animal models (DIO-NASH and DIO mice). It is now at the IND-enabling stage, and should be a "First in Human" therapeutic exosome in the clinic by 2025. This near-clinical exosome application has strong potential for success in commercially attractive therapeutic indications. We are looking for partners to develop and extend this innovative exosome product, enabling repeated, well-tolerated dosing to improve current treatments. In addition, our aim is to raise a Series A financing of € 18 M to finalize our activities, up to IND submission, and set up a Phase I clinical trial, while reinforcing the development of our platform.

### Participants

**Presenter: Robert Mamoun** - CEO, Ciloa

## Revolutionizing drug development: the symbiotic ecosystem of biotechs, research partners and innovative funding models

13:30 - 14:00

Ecosystem Innovation

### Location: Exhibit hall stage

In the dynamic landscape of drug development innovation, the synergy between biotechs, research partners, and innovative funding models has emerged as a driving force. This symposium explores the intricate relationships and collaborative efforts that are reshaping the future of drug development. Through insightful discussions and expert insights, participants will gain a deeper understanding of how these entities interact, leverage each other's strengths, and propel groundbreaking discoveries forward. Join us as we delve into how to revolutionize the drug development ecosystem where scientific advancements, entrepreneurial spirit, and strategic financing converge will shape a better tomorrow.

### Participants

**Moderator: Emily Mitchell** - VP, General Partner, ICON plc

**Panelist: Hubert Birner** - Managing Partner, TVM Capital

**Panelist: Renee Williams** - Founder and Managing Partner, Williams Biotech Consulting, LLC

## Metabolic Diseases: CK Regeon Inc.

13:30 - 13:45

Company Presentations: Room 133/134

### Location: Room 133/134

Founded in 2016, CK Regeon Inc. is developing First-in-class small molecule drugs which could restore damaged tissues of target diseases by restorative activation of the regenerative Wnt/ $\beta$ -catenin signaling. The targeted diseases include obesity, diabetes, NASH, and Alzheimer's.

Our platform technology is a regenerative therapy by safe activation of the Wnt signaling which was suppressed in patient tissue cells by interfering function of CXXC5, a negative regulator of the WNT pathway.

CXXC5 functions via binding at an upstream component, Dishevelled (Dvl), controlling the whole Wnt/ $\beta$ -catenin pathway involving regeneration of the damaged tissues of patients. The Wnt/ $\beta$ -catenin pathway is suppressed by cytosolic overexpression of CXXC5 in the patient tissue cells of the target diseases.

The function control of CXXC5 by interfering its binding with Dvl results in therapeutic effects for the diseases suppressed Wnt/ $\beta$ -catenin signaling, including obese-diabetes, NASH, and Alzheimer's.

Currently, our interest is obesity with diabetes. We confirm CXXC5 overexpression with the suppression of Wnt/ $\beta$ -catenin signaling in the tissue cells of both patient and animal models of the high fat diet (HFD) or db/db mutation.

We confirmed the CXXC5-Dvl PPI as a target for developing obesity and diabetes drugs by pathophysiological analyses of Cxxc5<sup>-/-</sup> mice as well as by efficacy tests of the CXXC5-Dvl PPI inhibitor. CK Regeon develops small-molecule candidates revealing potent therapeutic effects by initial HTS of the compound library, followed by their evolution through long historical chemical synthesis and characterization.

Our candidates reveal excellent therapeutic efficacies (20% weight loss in HFD-obesity model) without any significant side effects based on preclinical studies, including histochemical pathological analyses. These candidates could be developed as first-in-class, oral small-molecule drugs which potentially could replace GLP-1R agonist therapies.

### Participants

**Presenter: Kang-Yell Choi** - CEO, CK Regeon Inc.

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Cell and Gene Therapies: Advesya

13:45 - 14:00

Company Presentations: Room 133/134

**Location: Room 133/134**

Advesya is a French-Swiss startup biotech. The company is focusing on IL-1RAP as a pathway and our most advanced program (a CAR-T in AML) is going into clinic very soon. Our second program is an ADC against IL-1RAP for the treatment of solid malignancies.

### Participants

**Presenter: Richard Sainson** - CSO, Advesya

## Startup stories: how it started, how it's going

14:00 - 14:45

Startup Spotlight

**Location: Room 112**

From winning the startup pitch competition in 2017, forgoing a photoshoot opportunity with Messi, to secure funding, and debuting with Nike, join this session to delve into the evolution of Peptomyc. Hear about their entrepreneurial journey, how they have navigated the dynamic startup landscape and the challenges, triumphs and lessons learnt along the way. Further, understand from a VC perspective why Peptomyc shone bright and takeaway tips on how to drive a startup to success.

### Participants

**Moderator: Montserrat Vendrell** - Partner, Aliath Bioventures

**Panelist: Marie-Eve Beaulieu** - CSO, PEPTOMYC

**Panelist: Laura Soucek** - CEO, PEPTOMYC

## Cell and Gene Therapies: EG 427

14:00 - 14:15

Company Presentations: Room 133/134

**Location: Room 133/134**

EG 427 is the second company to bring a non-replicating HSV-1 vector into clinical development with an IND filing with the FDA in early 2024. Our unique platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Our vectors can achieve focal transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows either for long-term gene therapy, or all-in-one gene editing approaches.

### Participants

**Presenter: Philippe Chambon** - CEO and Co-Founder, EG 427

## Cell and Gene Therapies: Accelerated Biosciences Corp.

14:15 - 14:30

Company Presentations: Room 133/134

**Location: Room 133/134**

Accelerated Biosciences is a regenerative medicine company with freedom-to-operate for the human Trophoblast Stem Cell (hTSC) platform with 49 patents granted. We are providing GMP cells with a complete regulatory package to help cell and gene therapy developers accelerate their product time to market by 3 to 5 years with a potential \$10M in savings. We have effectively de-risked the starting cell source decision for the regenerative medicine industry. We are available for partnering and licensing opportunities.

### Participants

**Presenter: Yuta Lee** - CEO, Accelerated Biosciences Corp.

## Cell and Gene Therapies: Virica Biotech

14:30 - 14:45

Company Presentations: Room 133/134

**Location: Room 133/134**

We believe that current viral vector optimization technologies fall short because they fail to address a fundamental challenge, innate cellular antiviral defenses. Viral vectors used in gene therapy and vaccine applications trigger these antiviral defenses which prevents optimal production, leading to lower yield, efficiency, and limited scalability. Virica has developed a unique approach to addressing this challenge, a platform of Viral Sensitizers (VSETM) which help reduce antiviral defenses thereby increasing yield and improving critical quality attributes.

### Participants

**Presenter: Ella Korets-Smith** - CSO, Virica Biotech

## Cell and Gene Therapies: EXO Biologics

14:45 - 15:00

Company Presentations: Room 133/134

**Location: Room 133/134**

At EXO Biologics, we are united around our belief in the therapeutic potential of Exosomes. Our mission is to provide affordable and accessible therapy to patients with unmet medical needs.

Founded in Liège in 2019, EXO Biologics works closely with Professor M. Muraca, affiliated with the University of Padua.

At EXO Biologics, we have successfully overcome the challenge of consistent and large-scale production by internally developing a unique production platform. This breakthrough has opened up many potential clinical applications for cell-free and exosome-only-based therapies.

### Participants

**Presenter: Hugues Wallemacq** - CEO, EXO Biologics

## Startup spotlight pitch competition

15:00 - 17:00

Startup Spotlight

**Location: Room 112**

The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe audience. A panel of esteemed judges will evaluate the pitches and select the winners.

### Participating Companies:

Convert Pharmaceuticals

Elastrin Therapeutics Limited

Lovaltech

Mabswitch Inc

Nanological

Scarlet Therapeutics Ltd

Tabrix

The Blue Box Biomedical Solutions

### Participants

**Judge: Stephanie Marrus** - Managing Director, University of California San Francisco

**Judge: Hakan Goker** - Managing Director, M Ventures

**Judge: Raul Martin** - Partner, Ysios Capital

**Judge: Oscar Perez** - CSO, Ferrer

# SESSIONS

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Break and breathe

15:30 - 15:45

Break and breathe

**Location:** EBD booth

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

Sustainability Focus Area: Social Responsibility

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

## Unleashing healthcare: the power of AI, data, and personalized therapies

16:00 - 16:45

Business of Biotech

**Location:** Room 111

Join us to discuss how Biotech and Pharma stakeholders are diving into the dynamic landscape of digital technologies, with a focus on personalized treatments and Artificial Intelligence (AI). This panel will delve into the actionable strategies and impactful outcomes of leveraging a wealth of data in the context of developing and commercializing molecular assets. From real-world applications to the transformative potential of AI, participants will gain valuable insights into innovations that combine technology and life sciences. Don't miss this opportunity to unravel the synergies already shaping the future of healthcare.

### Participants

**Moderator :** Bjorn Arvidsson - Managing Director, STUNS Life Science

**Panelist:** Amparo Cuellar - Business Development Director, BioLizard

**Panelist:** Victor Guallar - ICREA Research Professor, Barcelona Supercomputing Center

**Panelist:** Jessica Shull - Director of Digital Therapeutics, Vicore Pharma AB

**Panelist:** Prabhu Velusami - Senior Director, Early Innovation Partnering (Retina & Data Sciences), Johnson & Johnson Innovation

**Panelist:** Friedrich Von Bohlen - Co-Founder and CEO, Molecular Health GmbH

## The push and pull of talent: lessons from Barcelona

16:00 - 16:30

Ecosystem Innovation

**Location:** Exhibit hall stage

How are you adjusting to the evolving landscape where Life Sciences & Health professionals increasingly prefer to work where they live? The industry has long grappled with talent shortages, but the post-pandemic era has accelerated the need for companies to rethink their approach.

In the past, companies held the allure, drawing talent to their locations. Now, the paradigm has shifted. It's talent that dictates the gravitational pull, not companies. Talent is the new gravity.

What implications does this shift have for your company's growth and its ability to attract top-tier talent? What lessons should we learn from this new reality?

Join a panel of industry frontrunners from Barcelona to explore how they're navigating this new landscape. Discover their strategies for attracting, developing, and retaining talent successfully. Remember, exceptional talent is the cornerstone of exceptional companies—don't risk falling behind.

### Participants

**Moderator:** Koen Vandecaveye - Director of Investment Promotion, Barcelona & Partners

**Panelist:** Juan Diego Casas - Global Talent Scout, AstraZeneca

**Panelist:** Gonzalo Parra - Bioinformatics Researcher, Barcelona Supercomputing Center

**Panelist:** Valerie Vanhooren - CEO, Ona Therapeutics

**Panelist:** Sonia Velasco - Partner, Cuatrecasas

## Exhibit hall reception

18:00 - 21:00

**Location:** CCIB, Exhibit Hall

**Time:** 18:00 – 21:00

### Exhibitors:

- Almirall - booth #42
- Belgium: wallonia and BioWin - booth #7
- BioM and Bayern International - booth #86
- BioPartner UK - booth #30
- Biocat – booth #20
- Citeline – booth #92
- Clarivate Analytics – booth #88
- Health Holland – booth #91
- Novartis - booth #53
- Prague Bio - booth #4
- Swiss Biotech and Superlab Suisse – booth #85
- BioRender #51
- WuXi AppTec #78
- Schott Pharma #16



# SCHEDULE

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	LUNCH	BUSINESS OF BIOTECH.	BREAK AND BREATHE	STARTUP SPOT-LIGHT
<b>06:00</b>	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run	<b>06:30</b> - Rise & Run
<b>08:00</b>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p><b>08:00</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p><b>08:30</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>
<b>09:00</b>	<p><b>09:00</b> - A breakfast mingle by the YVC Collective</p>	<p><b>09:30</b> - Pharma Company Presentation – Sanofi</p> <p><b>09:45</b> - Neuroscience frontier: identifying opportunities of transformative therapies for neurological conditions</p>	<p><b>09:30</b> - Navigating the biopharma services landscape: current state and future perspectives</p>		<p><b>09:45</b> - Infectious Diseases and Immunization: IAVI</p>				

# SCHEDULE

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17-19, 2025 | Milan, Italy

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	LUNCH	BUSINESS OF BIOTECH.	BREAK AND BREATHE	STARTUP SPOTLIGHT
10:00	10:00 - In collaboration with YVC Collective - In sync or offbeat: are the expectations of VCs and entrepreneurs aligned?		10:30 - EIB venture debt and its catalytic role in the venture financing ecosystem	10:15 - CNS/Neurology: Neurocentrx Pharma Ltd 10:30 - CNS/Neurology: NEWRON PHARMACEUTICALS SPA 10:45 - CNS/Neurology: Tonix Pharmaceuticals Holding Corp.	10:00 - Infectious Diseases and Immunization: ingineeon 10:15 - Diagnostics/ Technology and Digital Tools: 4D Lifetec AG 10:30 - Diagnostics/Technology and Digital Tools: Seek Labs 10:45 - Diagnostics/Technology and Digital Tools: GenEndeavor LLC				

# SCHEDULE

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17-19, 2025 | Milan, Italy

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	LUNCH	BUSINESS OF BIOTECH.	BREAK AND BREATHE	STARTUP SPOTLIGHT
11:00	11:00 - New generation of life science venture investing		11:30 - A new home: why is Paris region the ideal base to develop your biotech startups?	11:00 - CNS/Neurology: Addex Therapeutics Ltd 11:15 - CNS/Neurology: STALICLA SA 11:30 - Immunology: T-knife Therapeutics 11:45 - Immunology: Mestag Therapeutics	11:00 - Autoimmune/Inflammation: Halia Therapeutics 11:15 - Autoimmune/Inflammation: Artax Biopharma 11:30 - Autoimmune/Inflammation: Noa Therapeutics 11:45 - Dermatology: Alphyn Biologicals				
12:00		12:00 - Closing the gap: the imperative for women's health in biopharma		12:00 - Oncology: NUAGO Therapeutics Inc 12:45 - Pharma Company Presentation - MSD	12:00 - Ophthalmology: Guangzhou Ocusun Ophthalmic Biotechnology Co.Ltd	12:00 - Lunch		12:30 - Break and breathe	

# SCHEDULE

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	LUNCH	BUSINESS OF BIOTECH.	BREAK AND BREATHE	STARTUP SPOTLIGHT
13:00	13:00 - Perspectives for partnering success: communicating commercial appeal of early-stage assets		13:30 - Revolutionizing drug development: the symbiotic ecosystem of biotechs, research partners and innovative funding models	13:00 - Metabolic Diseases: Caledon Bioscience Inc. 13:15 - Metabolic Diseases: Ciloa 13:30 - Metabolic Diseases: CK Regeon Inc. 13:45 - Cell and Gene Therapies: Advesya			13:00 - Day in the life of an experienced dealmaker		
14:00				14:00 - Cell and Gene Therapies: EG 427 14:15 - Cell and Gene Therapies: Accelerated Biosciences Corp. 14:30 - Cell and Gene Therapies: Virica Biotech 14:45 - Cell and Gene Therapies: EXO Biologics					14:00 - Startup stories: how it started, how it's going
15:00								15:30 - Break and breathe	15:00 - Startup spotlight pitch competition

# SCHEDULE

DAY 2 - 19/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17-19, 2025 | Milan, Italy

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM 133/134	COMPANY PRESENTATIONS: ROOM 131/132	LUNCH	BUSINESS OF BIOTECH.	BREAK AND BREATHE	STARTUP SPOT-LIGHT
16:00	16:00 - Unleashing healthcare: the power of AI, data, and personalized therapies		16:00 - The push and pull of talent: lessons from Barcelona						
18:00	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception	18:00 - Exhibit hall reception

# SESSIONS

DAY 3 - 20/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

---

## Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)

07:45 - 08:15

Location: **CCIB Barcelona**

Light Breakfast: **served until 10:45**

---

## Partnering: one-to-one meetings (8:00 - 17:00 CET)

08:15 - 08:45

One-to-one meetings at BIO-Europe Spring will be scheduled during the hours below:

Meetings on this day will start at **8:00 - 17:00 CET**.

---

## Break and breathe

09:00 - 09:15

Break and breathe

Location: **EBD booth**

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

Sustainability Focus Area: Social Responsibility

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

---

---

## Next Generation: NanoMedSyn

09:30 - 09:40

Company Presentations: Exhibit Hall Stage

Location: **Exhibit hall stage**

NanoMedSyn develops proprietary vectors for drug delivery and protein degraders. Our drug-engineering platform is using a membrane receptor for endocytosis and degradation of pathogenic proteins in lysosomes. Applications concern immunotherapies of cancers, inflammatory and autoimmune diseases.

### Participants

**Presenter: Marie Maynadier** - General Manager, NanoMedSyn

---

## Next Generation: Menten AI, Inc.

09:40 - 09:50

Company Presentations: Exhibit Hall Stage

Location: **Exhibit hall stage**

Backed by top VCs including Uncork Capital, Khosla Ventures, and Y-Combinator, Menten AI is building generative AI to design next-generation macrocyclic therapeutics for challenging drug targets. It's the first platform capable of designing potent and membrane-permeable macrocycles in a matter of days. The team has demonstrated the robustness of their platform for complex drug targets including protein-protein interfaces and intracellular targets and has partnerships with top-10 pharma to accelerate their preclinical drug discovery efforts.

### Participants

**Presenter: Hans Melo** - CEO, Menten AI, Inc.

---

---

## Next Generation: StemcellX Limited

09:50 - 10:00

Company Presentations: Exhibit Hall Stage

Location: **Exhibit hall stage**

StemcellX was established with the mission to bring a novel, stem cell-based regenerative treatment for Osteoarthritis (OA). We bring together a strong and experienced team from the UK and Europe to develop fully licensed products for the benefit of the millions of humans & animals suffering from chronic pain, caused by this debilitating disease.

We have strong academic and industry partnerships in the UK, supporting our R&D programmes, including NGOs, Universities and independent professionals. We also have a highly experienced R&D operation and a purpose built, GMP compliant cell production facility in Hungary.

Our first product, developed for dogs, is now entering final regulatory trials. Using our production technologies, we began to develop a stem cell treatment for human Osteoarthritis and are currently pursuing a preclinical programme. The feasibility and effectiveness of our approach has recently been showcased by our treatment of an OA sufferer, elderly Gorilla in Budapest Zoo, the first ever primate to benefit from such medication. Since her treatment in August 2023, her quality of life has been transformed, demonstrating the safety and life-changing efficacy our stem cell products in one of our closest relatives.

### Participants

**Presenter: Endre Kiss-Toth** - Founder, CEO, StemcellX Limited

---

# SESSIONS

DAY 3 - 20/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Next Generation: ANYO Labs

10:00 - 10:10

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

ANYO Labs is an early drug discovery company with a novel patent pending artificial intelligence scoring method that addresses the major bottlenecks of speed, accuracy, and lack of novel compounds for difficultly drug-able targets.

The methods, stemming from computational and theoretical chemistry research allow for extreme data and energy efficient ways of finding drug compounds for further testing in the lab and clinical trials. The predictive accuracies top 3 different benchmarks in scoring, screening, and ranking power.

We have incorporated in december 2022, secured initial funding, have validated our technology through benchmarks, case studies, customer interviews, a pilot project, and worked with customers from academia and biotech companies. The first user cases revealed experimentally validated hits in fractions of the costs in a months time for an infectious disease target. Our current projects focus on inflammatory and oncological targets, and have the capacity to collaborate with small molecular targets outside of these disease areas as well.

ANYO Labs now looking into synthesising proprietary compounds for hard to drug targets in neoplasms as well as neglected diseases, and are looking for strategic partners as well as biotech companies willing to try to apply our product in their R&D.

### Participants

**Presenter: Marek Szczygiel** - Co-founder and CMO, ANYO Labs

## Next Generation: Avanzanite Bioscience

10:10 - 10:20

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Avanzanite Bioscience is a European-focused commercial-stage pharmaceutical company with a mission to accelerate patient access to ultra orphan or otherwise niche drugs for everyone in Europe, when nobody else dares to commercialise these products.

Derived from the word 'Tanzanite' - one of the rarest gemstones on earth - Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnership with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets; this is the unique expertise and core competency of the Avanzanite team through its decades of operating experience navigating this area. Equally important, the Company's humanitarian goal stems from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where they live in Europe.

We offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. Many of these biotechs develop breakthrough Orphan Drugs, however they often do not reach patients in need which is a shame and unfair. At Avanzanite, we believe patients with Rare Diseases should have access to the latest medical innovations regardless of where they live.

Avanzanite's founding mission is to tackle these critical issues in the European orphan drug space with our unique business model.

### Participants

**Presenter: Eva Cruz de Castro** - Head of Business Development, Avanzanite Bioscience

## Next Generation: MitoRx Therapeutics Limited

10:20 - 10:30

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

MitoRx Therapeutics is an Oxford-based first-in-class first-in-mechanism preclinical stage platform biotech developing highly potent small molecule therapeutics that halt progression in degenerative diseases whose pathology is driven by mitochondrial dysfunction. We achieved platform proof-of-concept Q4 2023 in mammalian disease models. Our internal foci are neurodegenerative and neuromuscular disease (NMD). \$5m seed financing has been raised since 2022 facilitating platform validation in mammalia and generating derisked front-running leads with the potential to become clinical candidates. MitoRx seeks investors to lead or co-lead an aggressive Series A to take forward up to two programs to early efficacy readouts in the clinic.

Pre-clinical results in mammalian disease models demonstrate that our leads are functionally protective in neuromuscular (DMD) and inflammatory disease (COPD, anti-fibrotic, for partnering), and we have an active pre-clinical program in neurodegenerative disease (Huntington's disease) reporting Q2 2024 pending expansion to broader neurodegenerative disease indications. Previous in vivo results demonstrate our approach is neuroprotective. DMD patient-derived cell-based work demonstrates restoration of mitochondrial ROS to healthy patient levels.

MitoRx is the sole biotech globally which has developed technology that restores the functional S-persulfidation post-translational signalling system regulating mitochondrial metabolism whose disruption has been demonstrated in Huntington's disease, Parkinson's disease, Alzheimer's disease, Duchenne muscular dystrophy and other progressive degenerative conditions.

MitoRx expects to be the only mitochondrial platform biotech globally to demonstrate utility in neuromuscular, neurodegenerative and inflammatory disease models. Multiple asset classes allow MitoRx to take a flexible approach in interactions with pharma.

### Participants

**Presenter: Jonathan Rees** - CEO, MitoRx Therapeutics Limited

# SESSIONS

DAY 3 - 20/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17–19, 2025 | Milan, Italy

## Next Generation: Exazyme GmbH

10:30 - 10:40

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Exazyme's mission is to make designing chemistry and biology as easy as using an app – facilitating the ideas that shorten the wait to solve the world's most pressing problems: from CO<sub>2</sub> to cancer.

With Exazyme's app, biotech innovators can discover the best possible protein for their goals while drastically reducing the number of experiments required. They may need 100 times fewer experiments than with standard methods – and achieve superior results. Exazyme is used by protein engineers in the pharmaceutical, industrial biotechnology and green biotechnology industries.

The app helps to design better drugs and therapies, chemicals and food, and improve plant properties for hardiness, productivity, and CO<sub>2</sub> absorption.

Breakthroughs in collaborations, such as with Max Planck, demonstrate our success. In a recent project, we engineered a biocatalyst for rapid CO<sub>2</sub> fixation, outperforming existing methods by far. Exazyme's AI streamlined the engineering of the key carboxylase in synthetic CO<sub>2</sub> fixation and reduced the screening effort. By doing so, we provide two novel enzymes with 2-fold improved carboxylation rate and 60 % reduced energy demand that are able to overcome the thermodynamic limitations of the tartronyl-CoA (TaCo) pathway, a synthetic photorespiration bypass that was recently designed to improve photosynthetic CO<sub>2</sub> fixation. (more details can be read here: <https://pubs.acs.org/doi/10.1021/acssynbio.3c00403>)

### Participants

**Presenter: Ingmar Schuster** - CEO & Co-Founder, Exazyme GmbH

## Business development round-up “have we got a deal? - key takeaways from this week's partnering meetings”

11:00 - 11:45

Business of Biotech

### Location: Exhibit Hall Stage

Seasoned life science business development professionals will share invaluable learnings and observations from the event, blending content insights with firsthand experiences and peer-to-peer networking encounters. They will explore the evolving landscape of business development, share strategic perspectives, and uncover collaborative opportunities that shape the future of the BD domain in the life sciences industry.

### Participants

**Moderator: Mike Ward** - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

**Panelist: Carlos Buesa** - CEO, Oryzon Genomics

**Panelist: Claudia Blattner** - VP, Business Development, Immatics Biotechnologies GmbH

**Panelist: Jeremy Benattar** - Marketing Strategy Director, Adocia

**Panelist: Selwyn Ho** - CEO, Medigene

**Panelist: Patrick Meyer** - Senior Director Global Strategic BD, Rentschler Biopharma SE

## Lunch

12:00 - 14:00

Lunch

## Break and breathe

13:30 - 13:45

Break and breathe

### Location: EBD booth

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

Sustainability Focus Area: Social Responsibility

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

## Closing reception

16:00 - 17:30

**Location:** BioRegion of Catalonia Host Booth – 10 participants (booth #20)

Reception to welcome BIO-Europe Spring 2025 in Milan, March 17-19, 2025



# SCHEDULE

DAY 3 - 20/03/2024

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

Save the date

March 17-19, 2025 | Milan, Italy

TIME	LUNCH	BUSINESS OF BIOTECH	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE	BREAK AND BREATHE
<b>07:00</b>	<b>07:45</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	<b>07:45</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	<b>07:45</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	<b>07:45</b> - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)
<b>08:00</b>	<b>08:15</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)	<b>08:15</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)	<b>08:15</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)	<b>08:15</b> - Partnering: one-to-one meetings (8:00 - 17:00 CET)
<b>09:00</b>			<b>09:30</b> - Next Generation: NanoMedSyn <b>09:40</b> - Next Generation: Menten AI, Inc. <b>09:50</b> - Next Generation: StemcellX Limited	<b>09:00</b> - Break and breathe
<b>10:00</b>			<b>10:00</b> - Next Generation: ANYO Labs <b>10:10</b> - Next Generation: Avanzanite Bioscience <b>10:20</b> - Next Generation: MitoRx Therapeutics Limited <b>10:30</b> - Next Generation: Exazyme GmbH	
<b>11:00</b>		<b>11:00</b> - Business development round-up "have we got a deal? - key takeaways from this week's partnering meetings"		
<b>12:00</b>	<b>12:00</b> - Lunch			
<b>13:00</b>				<b>13:30</b> - Break and breathe
<b>16:00</b>	<b>16:00</b> - Closing reception	<b>16:00</b> - Closing reception	<b>16:00</b> - Closing reception	<b>16:00</b> - Closing reception